Toxys
Toxys is a Dutch biotech company.
- Company typePrivate
- Founded2014
- HeadquartersLeiden, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Toxys does
Toxys is a Dutch biotech company that provides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development. We aim to bring information to our customers that is essential to make informed decisions on which compounds to progress in the drug/compound development pipeline, thereby contributing to the development of better medicines and products and to reduce animal testing.
Toxys firmographics
Firmographics- Name
- Toxys
- Legal name
- Toxys B.V.
- Website
- http://toxys.com/
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Toxys is a Dutch biotech company.
- Ownership category
- akta.pro rank
Toxys industry classification
Industry- Product category
- In Vitro Toxicology Testing Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ)
Keywords
Where Toxys is headquartered
LocationHeadquarters
- HQ city
- Leiden
- HQ country
- Netherlands
- HQ region
- Europe
Offices3 records
Markets served
Toxys business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services: Toxys provides contracted laboratory testing services using its proprietary in vitro assays. Clients submit compounds for genotoxicity, developmental toxicity, or investigative toxicology testing and receive detailed reports including cytotoxicity data, genotoxicity assessments, and benchmark dose (BMD) analysis. Services are offered on a project-by-project basis with quotes provided based on study scope.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Custom contracted testing services with project-based pricing |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels8 records
Toxys product offering
Product offeringCore offering
Toxys is a Dutch contract research organization that delivers mechanism-based in vitro toxicology testing services for chemical, pharmaceutical, cosmetics, food/feed, and nanomaterial safety assessment. Its offering centers on proprietary reporter-cell and hiPSC-based assays (ToxTracker Suite, ReproTracker, ToxProfiler, MutaTracker, MitoToxScreen) and complementary GLP/non-GLP assays (comet, Hprt, clonogenic, Alamar Blue), provided as study-based testing services to industrial R&D and regulatory safety teams.
Product overview
Toxys is a Dutch biotech company offering a comprehensive portfolio of in vitro toxicity screening solutions organized into four service categories: Genetic Toxicology, Developmental Toxicology, Investigative Toxicology, and Cytotoxicity. The core platform is the ToxTracker Suite, which contains multiple mechanism-based genotoxicity assays (ToxTracker, ToxTracker ACE, ToxTracker AO, ToxTracker EMP, TubulinTracker) that can discriminate between DNA damage, oxidative stress, and protein damage mechanisms. The flagship ReproTracker assay uses human induced pluripotent stem cells (hiPSCs) for developmental toxicity assessment. Additional offerings include ToxProfiler/ToxProfiler MAX for investigative toxicology and standard cytotoxicity assays. The assays are designed to rapidly identify hazardous and carcinogenic properties of novel compounds during early drug development phases, contributing to reduced animal testing.
Differentiator
Problem solved
Functional benefit
Brands
- ToxTracker Suite: A collection of in vitro genotoxicity assays including ToxTracker, ToxTracker ACE, TubulinTracker, ToxTracker AO, and ToxTracker EMP that reliably identify genotoxic compounds and provide detailed insight into their mode-of-action.
- ToxTracker
- ReproTracker
- MutaTracker
- ToxProfiler
- ToxTracker Academy
Products and services
- ToxTracker Suite Mechanism-based in vitro genotoxicity assay suite using GFP reporter cell lines to detect DNA damage, oxidative stress, protein damage, and microtubule disruption in a single test, enabling discrimination between aneugens, clastogens, and other modes of action. Used by pharmaceutical, chemical, cosmetics, food, and nanomaterial safety teams for non-animal genotoxicity assessment.
- ReproTracker Developmental and reproductive toxicity testing service using human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes and neural cell models to detect human-relevant developmental and cardiotoxicity hazards without animal use. Targeted at cosmetics, pharmaceutical, and chemical safety programs needing human-relevant developmental toxicity data.
- ToxProfiler Investigative toxicology service providing targeted molecular biomarker profiling using qPCR and protein arrays to characterize the biological pathways activated by compounds of interest. Used for mechanism-of-action studies and follow-up of positive in vitro toxicology findings.
- ToxProfiler MAX Extended investigative toxicology service delivering a broader panel of molecular biomarkers (qPCR and protein arrays) than standard ToxProfiler, enabling more comprehensive pathway-level mechanistic profiling of compounds.
- MutaTracker Genetic toxicology service for the detection and quantification of mutations in mammalian cells using a reporter gene readout, supporting mutagenicity assessment of chemicals and pharmaceuticals.
- MitoToxScreen Mitochondrial toxicity screening service assessing mitochondrial membrane potential, respiration, and related endpoints to identify compounds that impair mitochondrial function, relevant for drug, chemical, and nanomaterial safety assessment.
- DNA Repair-Profiler Genetic toxicology service profiling cellular DNA repair pathway activity to characterize how cells respond to genotoxic insult, supporting mechanistic interpretation of DNA damage findings.
- In vitro comet assay Single-cell gel electrophoresis (comet) assay service for detection of DNA strand breaks in vitro, delivered as part of Toxys's genetic toxicology testing portfolio for regulatory and investigative purposes.
- Hprt mutation assay In vitro mammalian-cell gene mutation assay at the Hprt locus, used to assess mutagenic potential of test substances as part of regulatory genetic toxicology testing packages.
- Clonogenic survival assay In vitro cytotoxicity assay service measuring clonogenic survival of cells following compound exposure, used to assess cytostatic and cytotoxic effects in non-clinical safety studies.
- Alamar Blue assay In vitro cytotoxicity assay service using Alamar Blue (resazurin reduction) to measure cell viability and metabolic activity following compound exposure, used as a general cytotoxicity screen.
Quantifiable outcome
- ToxTracker identifies in vivo genotoxicants with ~90% accuracy while reporting on oxidative and ER stressors that induce misleading positive test results in vitro
- +3 more outcomes
Companies that use Toxys
Customer profileNamed customers8 records
Segments5 records
Ideal customer profiles4 records
Toxys technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Toxys partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and strategic.
- Institute for In Vitro Sciences (IIVS)coreExpanded strategic partnership to advance adoption of New Approach Methodologies (NAMs) in genetic toxicology. IIVS is a non-profit organization focused on advancing in vitro science. The partnership expansion aims to accelerate industry and regulatory acceptance of innovative in vitro methods for chemical safety assessment.
- Korean Institute of Toxicology (KIT)strategicMemorandum of Understanding signed at SOT 2026 Annual Meeting to advance collaboration in genetic toxicology. KIT is a Korean government research institute focused on toxicology. The MoU establishes a framework for joint development and knowledge sharing in the genetic toxicology field.
- Charles River LaboratoriescoreCollaboration to offer Charles River's clients access to ReproTracker for developmental toxicity testing. Charles River's Alternative Methods Advancement Project (AMAP) reinforces commitment to incorporating NAMs. This partnership provides Charles River's extensive DART client base access to Toxys's innovative in vitro developmental toxicity assay, complementing Charles River's traditional DART offerings.
- UnilevercoreCollaborative research on developmental and reproductive toxicity (DART) using NAMs. Unilever and Toxys scientists published on evaluation of a bioactivity and exposure-based NAM toolbox for NGRA frameworks. Joint development of ReproTracker for exposure-led in vitro developmental toxicity testing.
- HoneywellstrategicCollaboration on PFAS research published in Toxicology Letters. Utilized ToxProfiler and ReproTracker to assess toxicological mode-of-action and developmental toxicity of different PFAS compounds with varying carbon chain lengths.
- Health Canada and University of SwanseastrategicCollaboration to implement quantitative analysis (PROAST) of ToxTracker results for human risk assessment. Aimed at implementing point-of-departure metrics for in vitro genetic toxicity dose-response data.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Toxys competitors and assessment
Company assessmentBroad incumbents
- Charles River Laboratories: Largest preclinical CRO globally with end-to-end genetic toxicology and DART service offerings; Toxys' direct distribution partner for ReproTracker. Both compete and partner in the in vitro toxicology services market.
- BioReliance (Merck/Sigma-Aldrich): Commercial testing services arm of Merck KGaA offering genetic toxicology, virology, and biosafety testing using in vitro assays. Directly comparable contract genetic toxicology laboratory.
- Eurofins Scientific: Global testing laboratory network with strong genetic toxicology and REACH testing offerings. Competes for the same pharma/chemical client testing budgets.
- Labcorp Drug Development (Covance): Major clinical and preclinical CRO with comprehensive in vitro toxicology and DART service portfolios serving global pharma clients.
Direct peers
- Cyprotex (Evotec): Subsidiary of Evotec providing in vitro ADME and mechanistic toxicology services for pharma and chemical clients. Closest comparable for mechanism-based toxicology screening CRO business.
- Stemina Biomarker Discovery: US-based developer of stem cell-based developmental toxicity assays (devTOX). Closest peer in hiPSC-based developmental toxicology testing services.
- Institute for In Vitro Sciences (IIVS): Non-profit organization advancing in vitro science including genetic toxicology assay protocols. Toxys' expanded strategic partner and participant in NAM advocacy/training.
- Environmental Health Sciences (EHS) — Genetic Toxicology Testing: Independent GLP-compliant genetic toxicology and in vitro toxicology contract laboratory with comparable GLP in vitro assay menu (Ames, micronucleus, comet, HPRT).
- GenoSafe: French CRO specializing in genetic toxicology and biotechnology-based testing services, including gene therapy safety assessment. Mid-sized competitor in the European genetic toxicology market.
Emerging players
- Cellaria Biosciences: Emerging player offering cell-based assay development and in vitro toxicology services using reporter technologies, partially overlapping with Toxys' mechanism-based assay approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Toxys social profiles
Digital presenceToxys financial estimates
Financial estimateRevenue estimate
Valuation estimate
Toxys leadership team
Management profileNumber of profiles
Profiles8 records
Toxys funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Toxys M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Toxys
What does Toxys do?
Toxys is a Dutch contract research organization that delivers mechanism-based in vitro toxicology testing services for chemical, pharmaceutical, cosmetics, food/feed, and nanomaterial safety assessment. Its offering centers on proprietary reporter-cell and hiPSC-based assays (ToxTracker Suite, ReproTracker, ToxProfiler, MutaTracker, MitoToxScreen) and complementary GLP/non-GLP assays (comet, Hprt, clonogenic, Alamar Blue), provided as study-based testing services to industrial R&D and regulatory safety teams.
Is Toxys a public or private company?
Toxys is a private company. It is classified as venture growth investor backed and is currently operating.
When was Toxys founded?
Toxys was founded in 2014. It employs 1 to 10 people.
Where is Toxys based?
Toxys is headquartered in Leiden, Netherlands, in the Europe region.
How does Toxys make money?
One revenue line is on record: contract Research Services.
Who are Toxys's main competitors?
Broad incumbents on record are Charles River Laboratories, BioReliance (Merck/Sigma-Aldrich), Eurofins Scientific and Labcorp Drug Development (Covance). Direct peers are Cyprotex (Evotec), Stemina Biomarker Discovery, Institute for In Vitro Sciences (IIVS), Environmental Health Sciences (EHS) — Genetic Toxicology Testing and GenoSafe. Cellaria Biosciences is listed as an emerging player.
Does Toxys have an API?
No public API is recorded for Toxys.
What industry is Toxys in?
Toxys's product category is In Vitro Toxicology Testing Services. Its primary akta.pro industry code is HLAGAFAJ, In Vitro Toxicology (Cell-based/Organ-on-chip). Its NAICS code is 541714 and its SIC code is 8731.